Apolipoprotein (apo) C-II and apo C-III serum concentrations were investi gated in 119 normotriglyceridemic male subjects with peripheral arterial dis ease (PAD) or coronary heart disease (CHD) or without clinical manifestations of atherosclerotic disease. All subjects included in the study had similar blood levels of total cholesterol ( < 400 mg/dL). High-density lipoproteins cholesterol (HDL-C) subfractions and apo A-I serum levels were significantly lower in CHD patients, as were apo A-I/apo B and HDL-cholesterol/total cholesterol ratios. Apo C-II and apo C-III showed similar serum concentrations in all three groups of subjects, but apo C-II/apo C-III ratio was significantly lower in PAD patients as compared with that in CHD patients and control subjects.
This study confirms that PAD may be associated with a particular lipopro tein derangement that primarily involves very low-density lipoprotein catabo lism.
Get full access to this article
View all access options for this article.
References
1.
Ross R., Harker LA: Hyperlipidemia and atherosclerosis: Chronic hyperlipidemia induces lesion initiation and progression by endothelial cell desquamation and lipid accumulation . Science193:1094-1100, 1976 .
2.
Steinberg D. : Lipoproteins and the pathogenesis of atherosclerosis . Circulation3:508-514, 1987.
3.
NationalCholesterol Education Program. Report of the expert panel on population strategies for blood cholesterol reduction. US Department of Health and Human Service. National Institute of Health, publication No. 90-3046, 1990.
4.
EuropeanAtherosclerosis Society Study Group. The recognition and management of hyperlipidemia in adults. A policy statement of the European Atherosclerosis Society. Eur Heart J9:571-600, 1988.
5.
Assman G., Gotto AM Jr, Paoletti R.: The hypertriglyceridemias: Risk and management. Am J Cardiol68:1A-42A, 1991.
6.
Sirtori CR, Mancini M., Paoletti R.: Consensus Hypertriglyceridemia as a vascular risk factor. Eur Heart J11H:44-48, 1990.
7.
Castelli WP: Cholesterol and lipids in the risk of coronary artery disease. The Framingham Heart Study. Can J Cardiol4:5A-10A, 1988.
8.
Hamsten A., Walldius G., Dahlen G., et al: Serum lipoproteins of apolipoproteins in young male survivors of myocardial infarction. Atherosclerosis59:223-235, 1986.
9.
Reinhart RA, Gani K., Arndt MR, et al: Apolipoproteins A-1 and B as predictors of angiographically defined coronary artery disease. Arch Inter Med150:1629-1633, 1990.
10.
Cambien F., Warnet JM, Jacqueson A., et al: Relation of parental history of early myocardial infarction to the level of apoprotein B in men. Circulation76:266-271, 1987.
11.
Hughson WG, Mann JL, Garrod A.: Intermittent claudication prevalence and risk factors. Br Med J1:1379-1381, 1978.
12.
Fowkes Fgr, Housley E., Riemersma RA, et al: Smoking, lipids, glucose intolerance, and blood pressure as risk factors for peripheral atherosclerosis compared with ischemic heart disease in the Edinburgh artery study. Am J Epidemiol135:331-340, 1991.
13.
Bihari-Vargi M., Szekeley J., Gruber E.: Plasma high density lipoproteins in coronary, cerebral, and peripheral vascular diseases. The influence of various risk factors. Atherosclerosis40:337-345, 1981.
14.
Paucillo P. , Carlson LA, Eklund B., et al: Concentration and chemical composition of plasma lipoprotein subfractions in patients with peripheral vascular disease: Evidence for normal apolipoprotein B but low cholesterol ester content in small VLDL. Atherosclerosis58:123-137, 1985.
15.
Trayner IM, Mannarino E., Clyne Cac, et al: Serum lipids and high density lipoprotein cholesterol in peripheral vascular disease. Br J Surg67:497-499, 1980.
16.
Arber F., Darioli R., Monti M., et al: Interét du dosage du HDL-cholesterol dans le bilan des artériophaties des membres inferieurs. Schweiz Med Wochenschr11: 1969-1971, 1981.
17.
Steiner G., Schwartz L., Shumak S., et al: The association of increased levels of intermediate-density lipoproteins with smoking and with coronary artery disease. Circulation75:124-130, 1987.
18.
Krauss RM: Relationship of intermediate and low-density lipoprotein subspecies to risk of coronary artery disease. Am Heart J113:578-582, 1987.
19.
Senti M., Nogues X., Pedro-Botet J., et al: Lipoprotein profile in men with peripheral vascular disease. Role of intermediate density lipoproteins and apoprotein E phenotypes. Circulation85:30-36, 1992.
20.
Rifai N.: Lipoproteins and apoproteins. Arch Pathol Lab Med110:694-701, 1986.
21.
Schonfeld G. , George PK, Miller J., et al: Apolipoprotein CII and CIII levels in hyperlipoproteinemia. Metabolism28:1001-1010. 1979.
22.
Farish E., Fletcher CA: A comparison of two micro-methods for the determination of HDL2 and HDL3 cholesterol . Clin Chim Acta139:221-228, 1983.
23.
Armitage P., Berry G.: Statistical Methods in Medical Research, ed. 2. Blackwell Scientific Publications, Oxford1990, pp 200-215.
24.
Avogaro P., Cazzolato G., Bittolo Bon G., et al: Are apolipoproteins better discriminators than lipids for atherosclerosis ? Lancet1:901-903, 1979.
25.
Noma A., Yokosuka T., Kitamura K.: Plasma lipids and apolipoproteins as discriminators for presence and severity of angiographically defined coronary artery disease. Atherosclerosis49:1-7, 1983.
26.
Nikkila M., Koivula T., Niemela K., et al: High density lipoprotein cholesterol and triglycerides as markers of angiographically assessed coronary artery disease. Br Heart J63:78-81, 1990.
27.
Dionyssiou-Asterou A., Kalofoutis A.: Lipid levels in high density lipoprotein subfractions in smokers with peripheral vascular disease. Atherosclerosis57:343-346, 1985.
